Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: ser), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Serina Therapeutics’ disclosures can feel like navigating polymer chemistry while tracking cash burn. The company’s POZ Platform and multiple neurology trials load its 10-K with dense scientific detail, while 8-Ks can shift outlook overnight as FDA feedback arrives. If you have ever searched hundreds of pages for pipeline timelines or waited anxiously for Form 4 hints of executive confidence, you know the challenge.
Stock Titan solves it. Our AI annotates every document so “Serina Therapeutics annual report 10-K simplified” and “Serina Therapeutics quarterly earnings report 10-Q filing” surface R&D spend, cash runway and upcoming milestones in plain English. Need alerts for “Serina Therapeutics Form 4 insider transactions real-time”? We deliver them alongside contextual trend charts. The platform also labels “Serina Therapeutics 8-K material events explained”, turning raw filings into concise notes within minutes of appearing on EDGAR.
Use these insights to compare trial costs quarter over quarter, review “Serina Therapeutics proxy statement executive compensation”, or dive into “Serina Therapeutics earnings report filing analysis” ahead of capital raises. Whether you’re tracking “Serina Therapeutics insider trading Form 4 transactions”, studying “Serina Therapeutics executive stock transactions Form 4”, or simply “understanding Serina Therapeutics SEC documents with AI”, our real-time feed, AI-powered summaries and expert commentary keep you informed without wading through footnotes.
Serina Therapeutics (SER) reported an insider equity award. A director received a grant of 10,000 stock options on 11/07/2025 with an exercise price of $3.91 per share.
The options expire on 11/07/2035 and will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, contingent on continued service. Following the grant, the reporting person beneficially owns 10,000 derivative securities, held Direct (D). The grant price for the derivative security was listed as $0.
Serina Therapeutics (SER) reported an insider transaction by its Chief Scientific Officer. On 11/05/2025, the officer exercised stock options for 3,398 shares at $0.06 per share and sold 3,398 common shares at a $4.24 weighted average price, with individual sale prices ranging from $4.30 to $4.225.
Following the transactions, the non-derivative common stock balance reported was 0 shares direct. Derivative holdings reported included 397,686 stock options. The exercised option series listed an expiration of 05/06/2031.
Serina Therapeutics (SER): Form 4 insider activity. The Chief Scientific Officer exercised stock options for 3,102 shares at $0.06 on 11/04/2025 and sold 3,102 common shares at a weighted average price of $4.3953 the same day. Following these transactions, common stock beneficially owned was 0 shares direct. The filing notes the sale was executed in multiple trades between $4.65 and $4.35. The reporting person continues to hold 401,084 stock options, which are fully vested, expiring on 05/06/2031.
Serina Therapeutics (SER) reported that the U.S. Food and Drug Administration has placed a clinical hold on the company’s IND application for SER-252, its lead development program for advanced Parkinson’s disease. The update was announced on November 3, 2025.
The company furnished a press release as Exhibit 99.1 providing the regulatory update on the SER-252 program.
Serina Therapeutics (SER) reported an insider transaction by its Chief Scientific Officer. On 10/28/2025, the officer exercised 5,551 stock options at $0.06 per share and sold 5,551 shares at a weighted average price of $4.9615.
After these transactions, directly held common stock was 0 shares. The filing lists 404,186 derivative securities (stock options) beneficially owned following the transactions. The reported options are fully vested and carry an expiration date of 05/06/2031.
Serina Therapeutics (SER) disclosed an insider transaction by its Chief Scientific Officer. On 10/27/2025, the officer exercised 949 stock options at $0.06 and sold 949 common shares at a weighted average price of $5.1857, with sales ranging from $5.25 to $5.10. After these transactions, 0 common shares were beneficially owned directly, and 409,737 stock options remained outstanding and are fully vested.
Serina Therapeutics filed Amendment No. 1 to its definitive proxy for the November 7, 2025 Annual Meeting, updating disclosures for the proposal to approve, under NYSE American rules, the potential issuance of 20% or more of its outstanding common stock in connection with a Convertible Note and Warrants.
The update clarifies that approval is sought for compliance with Sections 711 and 713(a)Dr. Bailey is a director, under certain circumstances the issuance of shares to him pursuant to the Convertible Note and Warrants could be considered equity compensation under Rule 711, depending on the market price at each funding.
The company states that, without approval, it would be unable to issue 20% or more to the holders of the Convertible Note and Warrants, and that this limitation could have a material adverse effect on its financial condition. Proxies already received will continue to be voted as instructed unless changed.
Serina Therapeutics (SER) Chief Scientific Officer Randall Moreadith exercised stock options for 6,500 shares at $0.06 and sold 6,500 shares at a weighted average price of $4.9672 on 10/20/2025.
The sale occurred in multiple transactions between $5.02 and $4.88. Following the transactions, the Form 4 reports 0 shares of common stock directly owned and 410,686 derivative securities (stock options) beneficially owned. The exercised option was fully vested and carried a $0.06 exercise price with an expiration date of 05/06/2031.
Serina Therapeutics (SER) reported an insider transaction by its Chief Scientific Officer. On 10/13/2025, the officer exercised a stock option for 4,326 shares at $0.06 per share and sold 4,326 common shares at a weighted average price of $5.20, with individual sale prices ranging from $5.25 to $5.18. Following these transactions, common stock beneficially owned was 0 shares, and derivative securities beneficially owned were 417,186 stock options. The reported stock options are fully vested and carry an expiration date of 05/06/2031.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
